{"log_id": 7690791632579192147, "direction": 0, "words_result_num": 31, "words_result": [{"probability": {"variance": 2e-06, "average": 0.999076, "min": 0.992221}, "location": {"width": 824, "top": 174, "height": 53, "left": 237}, "words": "生恶性肿瘤129例,其中包括联合甲氨蝶呤和本品治疗2年的活性对照试验的"}, {"probability": {"variance": 6e-06, "average": 0.998365, "min": 0.989356}, "location": {"width": 825, "top": 223, "height": 53, "left": 236}, "words": "231名患者。这些临床试验中所观察到的比率和发病率与对全体人口的研究期望"}, {"probability": {"variance": 1.2e-05, "average": 0.998714, "min": 0.97989}, "location": {"width": 826, "top": 271, "height": 54, "left": 233}, "words": "值相同。在一项351名采用本品治疗2年以上的强直性脊柱炎患者的研究中,本"}, {"probability": {"variance": 3.8e-05, "average": 0.997988, "min": 0.964248}, "location": {"width": 826, "top": 320, "height": 54, "left": 232}, "words": "品治疗组报告了6例恶性肿瘤。在治疗其它适应症的患者中,报告了32例恶性"}, {"probability": {"variance": 1e-06, "average": 0.998739, "min": 0.996444}, "location": {"width": 327, "top": 368, "height": 40, "left": 230}, "words": "肿瘤和43例非黑色素瘤皮肤癌"}, {"probability": {"variance": 8.1e-05, "average": 0.99755, "min": 0.946742}, "location": {"width": 777, "top": 418, "height": 50, "left": 276}, "words": "在临床试验中有4410名成年银屑病应用本品治疗至36个月,约4278患者"}, {"probability": {"variance": 6.9e-05, "average": 0.997425, "min": 0.954281}, "location": {"width": 827, "top": 463, "height": 53, "left": 226}, "words": "年,淋巴瘤的发生率为每100个患者年0.05例,该发生率和普通人群相当。另"}, {"probability": {"variance": 5e-06, "average": 0.998834, "min": 0.988524}, "location": {"width": 828, "top": 510, "height": 56, "left": 223}, "words": "外,在上述的有对照的临床试验中,本品组和安慰剂组患者均未观察到淋巴瘤发"}, {"probability": {"variance": 0, "average": 0.999211, "min": 0.999211}, "location": {"width": 28, "top": 561, "height": 28, "left": 222}, "words": "生"}, {"probability": {"variance": 0.000105, "average": 0.996084, "min": 0.955756}, "location": {"width": 765, "top": 604, "height": 59, "left": 268}, "words": "在采用本品治疗类风湿关节炎、强直性脊柱炎和其他适症的临床试验中"}, {"probability": {"variance": 1.1e-05, "average": 0.998393, "min": 0.987412}, "location": {"width": 402, "top": 656, "height": 40, "left": 223}, "words": "716名患者中总共报告了18例淋巴瘤"}, {"probability": {"variance": 0.002442, "average": 0.984725, "min": 0.716743}, "location": {"width": 763, "top": 700, "height": 57, "left": 268}, "words": "上市后也报告了各种肿瘤,包括乳腺癌、肺癌和淋巴瘤(参见“特别警告”)"}, {"probability": {"variance": 0.013356, "average": 0.965052, "min": 0.52502}, "location": {"width": 780, "top": 748, "height": 56, "left": 262}, "words": "一项临床试验中,曾有治疗 Wegener肉芽肿患者出现恶性肿瘤的报告参见"}, {"probability": {"variance": 0.000195, "average": 0.991738, "min": 0.960626}, "location": {"width": 118, "top": 799, "height": 29, "left": 214}, "words": "临床试验)。"}, {"probability": {"variance": 2e-06, "average": 0.998957, "min": 0.996725}, "location": {"width": 150, "top": 847, "height": 31, "left": 211}, "words": "注射部位反应"}, {"probability": {"variance": 0, "average": 0.999069, "min": 0.999069}, "location": {"width": 73, "top": 821, "height": 82, "left": 999}, "words": "★"}, {"probability": {"variance": 0.001685, "average": 0.985038, "min": 0.818656}, "location": {"width": 853, "top": 887, "height": 74, "left": 257}, "words": "与安慰剂相比,使用本品治疗的风湿疾病患者的注射部位反应发生率明显增"}, {"probability": {"variance": 0.001842, "average": 0.979149, "min": 0.869786}, "location": {"width": 331, "top": 939, "height": 38, "left": 209}, "words": "高(本品治疗组36%,安慰剂组"}, {"probability": {"variance": 0.022512, "average": 0.949106, "min": 0.432116}, "location": {"width": 460, "top": 954, "height": 35, "left": 598}, "words": "包括红斑和/或瘙痒、疼痛或肿胀)注射部"}, {"probability": {"variance": 0.009747, "average": 0.979603, "min": 0.42205}, "location": {"width": 831, "top": 982, "height": 63, "left": 205}, "words": "位反应通常在第一个月发生发生频率在第一个月最高,随后逐渐降低注射"}, {"probability": {"variance": 0.011958, "average": 0.96179, "min": 0.463226}, "location": {"width": 832, "top": 1028, "height": 67, "left": 205}, "words": "部位反应的平均持实时间为35天。本品治疗组出现注射部位反应的患者大多数"}, {"probability": {"variance": 0.009698, "average": 0.961641, "min": 0.482522}, "location": {"width": 820, "top": 1078, "height": 62, "left": 202}, "words": "未子治疗,给矛治疗者中多数接受局部用药,例如糖皮质激素或者口服抗组胺药"}, {"probability": {"variance": 0.000195, "average": 0.996101, "min": 0.91681}, "location": {"width": 829, "top": 1129, "height": 55, "left": 201}, "words": "除此之外,部分患者还出现注射部位反应再现,即在最近一次的注射点有皮肤反"}, {"probability": {"variance": 3e-06, "average": 0.998974, "min": 0.990547}, "location": {"width": 829, "top": 1179, "height": 52, "left": 201}, "words": "应同时在多数的先前注射点也出现注射部位反应。这种反应一般为一过性的,而"}, {"probability": {"variance": 0, "average": 0.999765, "min": 0.999406}, "location": {"width": 199, "top": 1227, "height": 35, "left": 199}, "words": "且治疗后不再复发"}, {"probability": {"variance": 2e-06, "average": 0.998877, "min": 0.994587}, "location": {"width": 778, "top": 1274, "height": 54, "left": 247}, "words": "在斑块型银屑病患者中进行的对照试验表明,在给药的前12周内本品治疗"}, {"probability": {"variance": 0.002395, "average": 0.988222, "min": 0.718607}, "location": {"width": 702, "top": 1322, "height": 49, "left": 195}, "words": "组患者中约有13.6%,安慰剂治疗组中约有3.4%出现注射部位反应"}, {"probability": {"variance": 7.9e-05, "average": 0.996072, "min": 0.957673}, "location": {"width": 597, "top": 1370, "height": 46, "left": 248}, "words": "上市后曾观察到与本品治疗有关的注射部位的出血和瘀血"}, {"probability": {"variance": 0, "average": 0.999968, "min": 0.999924}, "location": {"width": 99, "top": 1417, "height": 31, "left": 195}, "words": "严重感染"}, {"probability": {"variance": 4e-06, "average": 0.998961, "min": 0.990383}, "location": {"width": 777, "top": 1465, "height": 52, "left": 241}, "words": "在类风湿关节炎患者的对照试验中,当本品治疗组和安慰剂组的治疗暴露时"}, {"probability": {"variance": 9.9e-05, "average": 0.997325, "min": 0.939753}, "location": {"width": 827, "top": 1512, "height": 51, "left": 191}, "words": "间相同时,两组报告严重感染(致命的、威胁生命的、需要住院的或需要抗生素"}], "language": 3}